Biosimilars Have Driven Down Cost of Infliximab Biosimilars Have Driven Down Cost of Infliximab

Biosimilars have driven down the costs of originator biologics, but it isn ' t clear whether those savings are being passed on to patients or increasing access to the drugs.MDedge News
Source: Medscape Gastroenterology Headlines - Category: Gastroenterology Tags: Gastroenterology Source Type: news